ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Clinical trials for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for hard-to-treat vasculitis: three new drug combos tested
Disease control Recruiting nowThis study is for adults with granulomatosis with polyangiitis (GPA), a rare disease that inflames blood vessels, who haven't improved with usual treatments. Researchers will compare three different drug strategies—adding a standard arthritis drug to rituximab, or using tocilizum…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 16, 2026 22:34 UTC
-
Experimental cell therapy targets severe autoimmune diseases in early trial
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and whether the treat…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Universal CAR-T cells take on lupus and more in early trial
Disease control Recruiting nowThis early-phase study tests a new type of CAR-T cell therapy (called KN3601) for people with severe autoimmune diseases like lupus, scleroderma, Sjögren's syndrome, rheumatoid arthritis, and vasculitis that haven't responded to standard treatments. The therapy uses specially eng…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New cell therapy hopes to tame autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these specially designed cells. The main goal is …
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New hope for vasculitis patients: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called tarperprumig in 75 adults with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal is to see if the drug is safe and can help control the disease and prevent flare-ups. Participants will receive…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC
-
Experimental cell therapy targets severe autoimmune Flare-Ups
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in 18 adults with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard therapies. Participants receive a single infusion of these specially designed cells. The main goal is to che…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
Experimental cell therapy aims to tame Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and vasculitis that have not responded to standard treatments. Participants receive a single infusion of these specially engineered cells. The main goal is to che…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 03, 2026 12:06 UTC